S 17092 (1-10 mg/kg; p.o.; 7 days) improves the performance of cognitive tasks (VDR, DMS, DA) in a dose-dependent manner in MPTP (HY-15608)-treated monkeys[1].
S 17092 (10 mg/kg; p.o.; 7 days and again 1 h before each daily memory test) alleviates the Scopolamine (HY-N0296)-induced memory deficit, improves learning and working memory performances in young, elderly and old C57BL/6 mice[1].
S 17092 (0.01-30 mg/kg; i.p.; 60 or 120 min before session 1 then 24 h later 60 or 120 min before session 2, respectively) dose-dependently increases the retention time, alleviating scopolamine-induced amnesia in rats[1].
S 17092 is a long acting PEP inhibitor (t1/2 > 9 h). The 50% inhibitory dose (ID50) for cortical PEP activity are 7.4 and 13.4 mg/kg at one hour after p.o. in Wistar rat and NMRI mouse, respectively[1].
| Animal Model: | 3-5 months old male C57BL/6 mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage (p.o.); twice daily for 7 days and 60 min prior to the training sessions |
| Result: | Correct responses in the experimental group were 55, 58, and 74% in sessions 1, 2, and 3, respectively. Performance in experimental group was similar to that in non-amnesic controls.
Improved learning and memory performances in young amnesic C57BL/6 mice.
|
| Animal Model: | Adult male Macaca fascicularis monkeys treated with MPTP[1] |
| Dosage: | 1, 3, 10 mg/kg |
| Administration: | Oral gavage (p.o.); 7 days |
| Result: | Significantly improved variable delayed response (VDR) performance (76.9% correct responses vs. post-MPTP only) at 3 mg/kg, but not at 1 or 10 mg/kg doses.
VDR performance tended to revert back to a normal delay-dependent pattern of response, performance significantly improved on shorter (2, 5, and 10 sec delay) but not on longer delay trials at the 3mg/kg dose. Improved performance on shorter delay trials was not seen with either the 1 or 10 mg/kg doses.
Significant improvements in DMS (delayed matching-to-sample) performance were observed after administration at either 3 or 10 mg/kg doses.
Significantly improved DA (delayed alternation) performance at the 3 mg/kg dose, from 79% at baseline to 90.6% after 7-days or longer treatments.
|
| Animal Model: | 21-22 and 25 months old C57BL/6 mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage (p.o.); 7 days and again 1 h before each daily memory test |
| Result: | With correct responses of 45 and 70% in control and experimental animals, respectively, in session 5 and 46 and 65%, respectively, in session 6 in 21-22 months old C57BL/6 mice.
Had a beneficial effect on the selective deficit observed 25 months old C57BL/6 mice.
|
| Animal Model: | Rats treated with scopolamine[1] |
| Dosage: | 0.01-30 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); 60 or 120 min before session 1 then 24 h later 60 or 120 min before session 2, respectively |
| Result: | Dose-dependently increased the retention time, alleviating scopolamine-induced amnesia.
The maximum effect using 10 mg/kg with the 60 min pretest dosing interval was achieved using 3 mg/kg in the 120 min tests, suggesting that brain neuropeptide turnover may have been increased by increasing the time interval between the administration and the test.
|
